Ignite Creation Date:
2025-12-25 @ 12:05 AM
Ignite Modification Date:
2025-12-25 @ 10:03 PM
Study NCT ID:
NCT01042158
Status:
COMPLETED
Last Update Posted:
2017-09-12
First Post:
2010-01-04
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Sponsor:
Johns Hopkins University
Organization:
Study Overview
Official Title:
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATPAHSS
Brief Summary:
This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease (PAH-SSD). Standard outcome measures such as six-minute walk distance (6MWD), New York heart Association (NYHA) classification, and hemodynamic measurements will be assessed, as well as novel functional measures of RV-PV function including the transthoracic echocardiogram parameter tricuspid annular plane systolic ejection (TAPSE), contrast-enhanced cardiac MRI and heart rate variability assessed by Holter monitoring. This design (excluding a placebo arm) was selected for ethical concerns and to provide optimal efficiency and active therapy to all study subjects. It also allows for comparisons between the two monotherapies and with combination therapy.
Detailed Description:
Pulmonary Arterial Hypertension (PAH) includes a heterogeneous group of clinical entities sharing similar clinical and pathological features that have been subcategorized as idiopathic PAH (IPAH, formerly known as "primary pulmonary hypertension" or PPH), familial PAH, pulmonary hypertension related to connective tissue diseases (such as systemic sclerosis), portopulmonary hypertension and pulmonary hypertension related to HIV infection, drugs and toxins (10). PAH is clinically defined by a resting mean pulmonary artery pressure ≥ 25 mmHg and pulmonary artery wedge pressure ≤ 15 mmHg in the absence of left heart disease, underlying parenchymal lung disease, thromboembolic disease or other causes of pulmonary hypertension.
PAH is characterized by increased pulmonary vascular resistance due to remodeling and occlusion of the pulmonary arterioles. Left untreated, PAH leads irremediably to right ventricular (RV) hypertrophy, pressure overload and dilation resulting in death within 2-3 years (11). For the past two decades, it has been appreciated that the integrity of the RV function, rather than the degree of pulmonary vascular injury, is the major determinant of symptoms and mortality in patients with PAH. RV dysfunction at time of presentation, as reflected by an elevation in right atrial pressure (RAP), the presence of pericardial effusion or depressed cardiac output (CO), is a powerful prognosticator of death (12).
Current PAH therapies consist of prostacyclin analogues, endothelin receptor antagonists (ETRA) and phosphodiesterase type V (PDE V) inhibitors (13). All have been shown to be effective in improving exercise capacity as measured by the 6 MWD in short term (12 - 16 week) randomized, placebo-controlled clinical trials. However, the clinical response is highly variable and mortality remains high (14). Moreover, the majority of subjects enrolled in these trials have had IPAH. Over the past 10 years, the Johns Hopkins Pulmonary Hypertension Program and Scleroderma Center have worked closely to address the daunting clinical challenge of PAH associated with scleroderma or systemic sclerosis (PAH-SSc). Previous work from our group (15;16) and others (17-19) has clearly demonstrated a markedly worse prognosis in PAH-SSc compared with IPAH despite similar treatments. An intriguing and consistent finding when comparing these two groups is that whereas mPAP is, on average, lower in PAH-SSc, markers of RV dysfunction (e.g. CO and RAP) are similar, raising the possibility of maladaptive RV response to pressure overload and/or intrinsic myocardial disease. Current PAH therapies target pathways that have been implicated in the remodeling of the pulmonary vasculature (PV). However, there is no clear evidence that these therapies have altered PV and/or RV remodeling or offered significant beneficial effects in patients with PAH-SSc in whom mortality remains exceedingly high. In addition, their effects on RV dysfunction and RV-PV interaction remain poorly characterized.
We hypothesize that improvement in PAH-SSc will only be achieved with therapy directly targeted at RV-PV dysfunction. Sildenafil and tadalafil inhibit phosphodiesterase type 5 (PDE5) which is abundant in the lung and is the main enzyme responsible for cyclic Guanosine MonoPhosphate (cGMP) hydrolysis. The resulting increase in cGMP probably mediates the relaxant and anti-hypertrophic actions of nitric oxide and natriuretic peptides in vascular tissues, and exerts a direct anti-hypertrophic action on cardiac muscle as demonstrated in compelling preliminary experiments by investigators of the NHLBI-funded Hopkins Scientific Center of Clinically Oriented Research (SCCOR) in Pulmonary Vascular Disease. In these experiments, sildenafil was capable of preventing and reversing RV hypertrophy and dysfunction in a model of pulmonary artery banding, similar to its effects on the left ventricle with aortic banding (20), indicating a direct beneficial action on RV remodeling.
Both sildenafil (21) and tadalafil (22) have been demonstrated to be effective in PAH and are FDA approved for this indication. The endothelin-receptor antagonists, bosentan (23) and ambrisentan (24), are also FDA-labeled for this indication and represent alternative options for oral therapy of PAH (25). A small randomized study comparing sildenafil with bosentan suggested that sildenafil was superior in reducing RV mass and improving exercise capacity in patients with PAH (26). Recently, the results of a large multi-center randomized, controlled trial of tadalafil therapy for PAH have been presented. The data indicate, that similar to sildenafil, tadalafil at doses of 20 and 40 mg per day, improved exercise capacity. In addition, tadalafil 40 mg per day improved pulmonary hemodynamics, quality of life and reduced the incidence of clinical worsening.
This study aims to compare the effects of upfront combination therapy with tadalafil and ambrisentan in PAH-SSc on PVR and RV mass. It will also assess novel markers of RV function by cardiac MRI and echocardiography, as well as the conventional endpoints, including 6 MWD and functional class. The trial is unique in that it will enroll only PAH-SSc patients, the PAH subgroup with the poorest outcomes and will be considerably longer in duration (36 weeks) than previous studies.
PAH is characterized by increased pulmonary vascular resistance due to remodeling and occlusion of the pulmonary arterioles. Left untreated, PAH leads irremediably to right ventricular (RV) hypertrophy, pressure overload and dilation resulting in death within 2-3 years (11). For the past two decades, it has been appreciated that the integrity of the RV function, rather than the degree of pulmonary vascular injury, is the major determinant of symptoms and mortality in patients with PAH. RV dysfunction at time of presentation, as reflected by an elevation in right atrial pressure (RAP), the presence of pericardial effusion or depressed cardiac output (CO), is a powerful prognosticator of death (12).
Current PAH therapies consist of prostacyclin analogues, endothelin receptor antagonists (ETRA) and phosphodiesterase type V (PDE V) inhibitors (13). All have been shown to be effective in improving exercise capacity as measured by the 6 MWD in short term (12 - 16 week) randomized, placebo-controlled clinical trials. However, the clinical response is highly variable and mortality remains high (14). Moreover, the majority of subjects enrolled in these trials have had IPAH. Over the past 10 years, the Johns Hopkins Pulmonary Hypertension Program and Scleroderma Center have worked closely to address the daunting clinical challenge of PAH associated with scleroderma or systemic sclerosis (PAH-SSc). Previous work from our group (15;16) and others (17-19) has clearly demonstrated a markedly worse prognosis in PAH-SSc compared with IPAH despite similar treatments. An intriguing and consistent finding when comparing these two groups is that whereas mPAP is, on average, lower in PAH-SSc, markers of RV dysfunction (e.g. CO and RAP) are similar, raising the possibility of maladaptive RV response to pressure overload and/or intrinsic myocardial disease. Current PAH therapies target pathways that have been implicated in the remodeling of the pulmonary vasculature (PV). However, there is no clear evidence that these therapies have altered PV and/or RV remodeling or offered significant beneficial effects in patients with PAH-SSc in whom mortality remains exceedingly high. In addition, their effects on RV dysfunction and RV-PV interaction remain poorly characterized.
We hypothesize that improvement in PAH-SSc will only be achieved with therapy directly targeted at RV-PV dysfunction. Sildenafil and tadalafil inhibit phosphodiesterase type 5 (PDE5) which is abundant in the lung and is the main enzyme responsible for cyclic Guanosine MonoPhosphate (cGMP) hydrolysis. The resulting increase in cGMP probably mediates the relaxant and anti-hypertrophic actions of nitric oxide and natriuretic peptides in vascular tissues, and exerts a direct anti-hypertrophic action on cardiac muscle as demonstrated in compelling preliminary experiments by investigators of the NHLBI-funded Hopkins Scientific Center of Clinically Oriented Research (SCCOR) in Pulmonary Vascular Disease. In these experiments, sildenafil was capable of preventing and reversing RV hypertrophy and dysfunction in a model of pulmonary artery banding, similar to its effects on the left ventricle with aortic banding (20), indicating a direct beneficial action on RV remodeling.
Both sildenafil (21) and tadalafil (22) have been demonstrated to be effective in PAH and are FDA approved for this indication. The endothelin-receptor antagonists, bosentan (23) and ambrisentan (24), are also FDA-labeled for this indication and represent alternative options for oral therapy of PAH (25). A small randomized study comparing sildenafil with bosentan suggested that sildenafil was superior in reducing RV mass and improving exercise capacity in patients with PAH (26). Recently, the results of a large multi-center randomized, controlled trial of tadalafil therapy for PAH have been presented. The data indicate, that similar to sildenafil, tadalafil at doses of 20 and 40 mg per day, improved exercise capacity. In addition, tadalafil 40 mg per day improved pulmonary hemodynamics, quality of life and reduced the incidence of clinical worsening.
This study aims to compare the effects of upfront combination therapy with tadalafil and ambrisentan in PAH-SSc on PVR and RV mass. It will also assess novel markers of RV function by cardiac MRI and echocardiography, as well as the conventional endpoints, including 6 MWD and functional class. The trial is unique in that it will enroll only PAH-SSc patients, the PAH subgroup with the poorest outcomes and will be considerably longer in duration (36 weeks) than previous studies.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| P50HL084946 | NIH | None | https://reporter.nih.gov/quic… | View |